GDC 4198
Alternative Names: GDC-4198; RGT-419BLatest Information Update: 28 Apr 2025
At a glance
- Originator Regor Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 negative breast cancer; Solid tumours
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO, Capsule)
- 28 Apr 2025 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (PO, Capsule)
- 30 Sep 2024 Genentech acquires RGT 419B from Regor